Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (161-170 of 324) with videos related to

Pageof 33
Sort By:
AIDS (London, England)|May 29, 2004
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohortW Phillip Law, Chris J Duncombe, Apicha Mahanontharit, et al.
AIDS Research and Human Retroviruses|July 13, 2013
Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreportingJohn M Murray, John J Zaunders, Kersten K Koelsch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 18, 2003
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjectsPeter G Cardiello, Tarkika Monhaphol, Apicha Mahanontharit, et al.
AIDS (London, England)|October 3, 2003
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001W Phillip Law, Gregory J Dore, Chris J Duncombe, et al.
The Journal of Infectious Diseases|October 29, 2008
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunctionPatrick W G Mallon, Rebecca Sedwell, Gary Rogers, et al.
Lancet (London, England)|August 8, 2006
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsCharles B Hicks, Pedro Cahn, David A Cooper, et al.
Immunology|November 24, 2012
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infectionLeia H Wren, Amy W Chung, Gamze Isitman, et al.
The American Journal of Tropical Medicine and Hygiene|February 27, 2020
The Influence of HIV Status on the Burden and Clinical Manifestations of Gastrointestinal Pathogens in Yangon, MyanmarWin Pa Pa Aung, Nan Phyu Sin Toe Myint, Thet Tun Zaw, et al.
Human Vaccines|October 3, 2006
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trialsRobert De Rose, Mark T Sullivan, C Jane Dale, et al.
Plos One|January 6, 2016
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialDavid A Cooper, Damien V Cordery, Roberto Zajdenverg, et al.
Pageof 33

Showing results (161-170 of 324) with videos related to

Sort By:
Pageof 33
AIDS (London, England)|May 29, 2004
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohortW Phillip Law, Chris J Duncombe, Apicha Mahanontharit, et al.
AIDS Research and Human Retroviruses|July 13, 2013
Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreportingJohn M Murray, John J Zaunders, Kersten K Koelsch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 18, 2003
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjectsPeter G Cardiello, Tarkika Monhaphol, Apicha Mahanontharit, et al.
AIDS (London, England)|October 3, 2003
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001W Phillip Law, Gregory J Dore, Chris J Duncombe, et al.
The Journal of Infectious Diseases|October 29, 2008
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunctionPatrick W G Mallon, Rebecca Sedwell, Gary Rogers, et al.
Lancet (London, England)|August 8, 2006
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsCharles B Hicks, Pedro Cahn, David A Cooper, et al.
Immunology|November 24, 2012
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infectionLeia H Wren, Amy W Chung, Gamze Isitman, et al.
The American Journal of Tropical Medicine and Hygiene|February 27, 2020
The Influence of HIV Status on the Burden and Clinical Manifestations of Gastrointestinal Pathogens in Yangon, MyanmarWin Pa Pa Aung, Nan Phyu Sin Toe Myint, Thet Tun Zaw, et al.
Human Vaccines|October 3, 2006
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trialsRobert De Rose, Mark T Sullivan, C Jane Dale, et al.
Plos One|January 6, 2016
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialDavid A Cooper, Damien V Cordery, Roberto Zajdenverg, et al.
Pageof 33